Literature DB >> 1676256

Enumeration of IgA producing cells by the enzyme linked immunospot (ELISPOT) technique to evaluate sulphasalazine effects in inflammatory arthritides.

N Feltelius1, S Gudmundsson, L Wennersten, O Sjöberg, R Hällgren, L Klareskog.   

Abstract

Numbers of IgA producing cells in peripheral blood were determined by the enzyme linked immunospot (ELISPOT) technique in 15 patients with inflammatory arthritides receiving sulphasalazine treatment. The numbers of IgA producing cells decreased significantly after the first three weeks of treatment. In 11 of the patients this decrease persisted, whereas a subsequent increase was seen in the four others; in two of these latter patients this increase coincided with a temporary withdrawal of the sulphasalazine treatment. A reduction of serum concentrations of IgA and haptoglobin was seen after three months' treatment. Eleven of the patients had a subjective improvement in their joint disease during the first three months of treatment. Analysis of circulating cells committed for IgA secretion may constitute one way of assessing gut associated immunity indirectly, and the present data suggest that sulphasalazine has a rapid effect on lymphocytes possibly originating from the gut and that such an effect precedes improvement in laboratory parameters and clinical symptoms in arthritic diseases.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1676256      PMCID: PMC1004439          DOI: 10.1136/ard.50.6.369

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  18 in total

1.  Sulfasalazine in the treatment of ankylosing spondylitis. A twenty-six-week, placebo-controlled clinical trial.

Authors:  M Nissilä; K Lehtinen; M Leirisalo-Repo; R Luukkainen; O Mutru; U Yli-Kerttula
Journal:  Arthritis Rheum       Date:  1988-09

2.  Immunoglobulin A in the skin of patients with ankylosing spondylitis.

Authors:  A Collado; R Sanmarti; I Bielsa; T Castel; E Kanterewicz; J D Cañete; M A Brancós; J Rotes-Querol
Journal:  Ann Rheum Dis       Date:  1988-12       Impact factor: 19.103

3.  Preliminary evidence for gut involvement in the pathogenesis of rheumatoid arthritis?

Authors:  A W Segal; D A Isenberg; V Hajirousou; S Tolfree; J Clark; M L Snaith
Journal:  Br J Rheumatol       Date:  1986-05

4.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

Authors:  F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra
Journal:  Arthritis Rheum       Date:  1988-03

5.  Sequential studies in ankylosing spondylitis. Association of Klebsiella pneumoniae with active disease.

Authors:  R W Ebringer; D R Cawdell; P Cowling; A Ebringer
Journal:  Ann Rheum Dis       Date:  1978-04       Impact factor: 19.103

6.  Sulphasalazine: a safe, effective agent for prolonged control of rheumatoid arthritis. A comparison with sodium aurothiomalate.

Authors:  D E Bax; R S Amos
Journal:  Ann Rheum Dis       Date:  1985-03       Impact factor: 19.103

7.  Circulating inhibitor bound elastase in patients with ankylosing spondylitis and rheumatoid arthritis and the influence of sulphasalazine treatment.

Authors:  N Feltelius; R Hällgren
Journal:  Ann Rheum Dis       Date:  1988-01       Impact factor: 19.103

8.  T lymphocytes in ankylosing spondylitis and the influence of sulphasalazine treatment.

Authors:  N Feltelius; R Hällgren; O Sjöberg
Journal:  Clin Rheumatol       Date:  1987-12       Impact factor: 2.980

9.  Sulphasalazine in ankylosing spondylitis: a double blind controlled study in 60 patients.

Authors:  M Dougados; P Boumier; B Amor
Journal:  Br Med J (Clin Res Ed)       Date:  1986-10-11

10.  Sulphasalazine in ankylosing spondylitis.

Authors:  N Feltelius; R Hällgren
Journal:  Ann Rheum Dis       Date:  1986-05       Impact factor: 19.103

View more
  4 in total

1.  Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression.

Authors:  J Rönnelid; M C Wick; J Lampa; S Lindblad; B Nordmark; L Klareskog; R F van Vollenhoven
Journal:  Ann Rheum Dis       Date:  2005-04-20       Impact factor: 19.103

2.  Sulphasalazine inhibits human antigen-specific immune responses in vivo.

Authors:  Christina Trollmo; Sveinn Gudmundsson; Nils Feltelius; Siv Rogberg; Göran Smedegård; Lars Klareskog
Journal:  Ann Rheum Dis       Date:  2006-09-19       Impact factor: 19.103

3.  Evidence for differential effects of sulphasalazine on systemic and mucosal immunity in rheumatoid arthritis.

Authors:  L Kanerud; G N Engström; A Tarkowski
Journal:  Ann Rheum Dis       Date:  1995-04       Impact factor: 19.103

4.  Variation in the serum IgA concentration and the production of IgA in vitro in rheumatoid arthritis treated by sulfasalazine.

Authors:  C Jorgensen; C Bologna; J M Anaya; T Reme; J Sany
Journal:  Rheumatol Int       Date:  1993       Impact factor: 2.631

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.